Published by Oliver Haill on 31st October 2017
(ShareCast News) - Oxford Biomedica received a boost as Novartis announced that it has filed for approval of its Kymriah drug for a second blood cancer indication.
URL: http://www.digitallook.com/dl/news/story/26636663/...